Stada Faces Damages On German Pemetrexed Reversal
Stada Launched ‘At Risk’ Following Invalidity Ruling
In its half-year report, Stada has confirmed it continues to face the threat of damages from Eli Lilly, following its ‘at-risk’ launch in Germany of an alternative to the originator’s Alimta in July 2018.
